Adverum Biotechnologies (LSE:0HA3) - Stock Price, News & Analysis

0HA3 Stock Overview

A clinical-stage company, develops gene therapy product candidates to treat ocular diseases. More details

0HA3 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 47.34% per year

Risk Analysis

Earnings are forecast to decline by an average of 16.9% per year for the next 3 years

Shareholders have been substantially diluted in the past year

Makes less than USD$1m in revenue ($1,000K)

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 1 more risk

Adverum Biotechnologies, Inc. Competitors

PureTech Health

LSE:PRTC

UK£415.6m

Faron Pharmaceuticals Oy

AIM:FARN

UK£159.6m

Bioventix

AIM:BVXP

UK£204.9m

e-therapeutics

AIM:ETX

UK£52.6m

Price History & Performance

Summary of all time highs, changes and price drops for Adverum Biotechnologies
Historical stock prices
Current Share Price	US$7.41
52 Week High	US$29.50
52 Week Low	US$6.43
Beta	1.01
11 Month Change	-4.88%
3 Month Change	12.96%
1 Year Change	-14.77%
33 Year Change	-63.64%
5 Year Change	-86.55%
Change since IPO	-89.41%

Recent updates

Shareholder Returns

	0HA3	GB Biotechs	GB Market
7D	-5.9%	-2.9%	-1.7%
1Y	-14.8%	-20.6%	5.1%

Return vs Industry: 0HA3 exceeded the UK Biotechs industry which returned -20.6% over the past year.

Return vs Market: 0HA3 underperformed the UK Market which returned 5.1% over the past year.

Price Volatility

Is 0HA3's price volatile compared to industry and market?
0HA3 volatility
0HA3 Average Weekly Movement	7.7%
Biotechs Industry Average Movement	9.8%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	10.0%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: 0HA3's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: 0HA3's weekly volatility has decreased from 13% to 8% over the past year, but is still higher than 75% of UK stocks.

About the Company

Founded	Employees	CEO	Website
2006	121	Laurent Fischer	adverum.com

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection.

Adverum Biotechnologies, Inc. Fundamentals Summary

How do Adverum Biotechnologies's earnings and revenue compare to its market cap?
0HA3 fundamental statistics
Market cap	US$157.27m
Earnings (TTM)	-US$94.11m
Revenue (TTM)	US$1.00m

150.8x

P/S Ratio

-1.6x

P/E Ratio

Is 0HA3 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0HA3 income statement (TTM)
Revenue	US$1.00m
Cost of Revenue	US$68.22m
Gross Profit	-US$67.22m
Other Expenses	US$26.89m
Earnings	-US$94.11m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-4.52
Gross Margin	-6,722.40%
Net Profit Margin	-9,411.10%
Debt/Equity Ratio	0%

How did 0HA3 perform over the long term?

See historical performance and comparison

0HA3 Stock Overview

Rewards

Risk Analysis

Adverum Biotechnologies, Inc. Competitors

LSE:PRTC

UK£415.6m

AIM:FARN

UK£159.6m

AIM:BVXP

UK£204.9m

AIM:ETX

UK£52.6m

Price History & Performance

Recent News & Updates

Adverum Biotechnologies, Inc. Appoints Jason L. Mitchell as Chief Commercial Officer

Adverum Biotechnologies Announces Fda Regenerative Medicine Advanced Therapy (Rmat) Designation Granted for Ixo-Vec for the Treatment of Wet Amd

Adverum Biotechnologies, Inc. Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting

Adverum Biotechnologies, Inc. Announces Executive Changes

Adverum Biotechnologies, Inc., Annual General Meeting, Jun 17, 2024

Adverum Biotechnologies, Inc. announced that it has received $127.5 million in funding from a group of investors

Recent updates

Adverum Biotechnologies, Inc. Appoints Jason L. Mitchell as Chief Commercial Officer

Adverum Biotechnologies Announces Fda Regenerative Medicine Advanced Therapy (Rmat) Designation Granted for Ixo-Vec for the Treatment of Wet Amd

Adverum Biotechnologies, Inc. Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting

Adverum Biotechnologies, Inc. Announces Executive Changes

Adverum Biotechnologies, Inc., Annual General Meeting, Jun 17, 2024

Adverum Biotechnologies, Inc. announced that it has received $127.5 million in funding from a group of investors

Adverum Biotechnologies, Inc. Announces Positive Preliminary Efficacy and Safety Data from Luna Phase 2 Trial of Ixo-Cov in Patients with Wet AMD

Adverum Biotechnologies, Inc. Announces Stipulation and Agreement of Settlement

Adverum Biotechnologies, Inc. announced that it expects to receive $127.5 million in funding from a group of investors

Adverum Biotechnologies, Inc. Appoints Romuald Corbau as Chief Scientific Officer and Member of Executive Committee

Adverum Biotechnologies Receives a Letter from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

Adverum Biotechnologies, Inc. Appoints C. David Nicholson to the Board of Directors

Adverum Biotechnologies, Inc. Announces Positive Aflibercept Protein Level Data from the Luna Phase 2 Trial

Adverum Biotechnologies, Inc. Appoints R. Andrew Andy Ramelmeier as Chief Technology Officer

Adverum Biotechnologies, Inc. Appoints R. Andrew Andy Ramelmeier as Chief Technology Officer

Adverum Biotechnologies, Inc. Completes Enrollment of Phase 2 LUNA Trial in Wet AMD

Adverum Biotechnologies Receives Nasdaq Notice on Regained Compliance with Minimum Bid Price Requirement

Adverum Biotechnologies, Inc. Announces Resignation of Richard Beckman as Chief Medical Officer

Adverum Biotechnologies, Inc. Receives Approval from the Listing Qualifications Department of Nasdaq to Transfer the Listing of Common Stock from Nasdaq Global Market to Nasdaq Capital Market

Adverum Biotechnologies, Inc. Presents Nonclinical Data in Support of Ixo-vec’s Phase 2 Clinical Development at ASGCT 2023 Annual Meeting

Adverum Biotechnologies, Inc. Appoints Linda Rubinstein as Chief Financial Officer

Adverum Biotechnologies, Inc. Announces New Data from the OPTIC Study Treating Wet Age-Related Macular Degeneration

Adverum Biotechnologies Announces First Subject Dosed with Ixo-vec in the Phase 2 LUNA Trial for the Treatment of Wet Age-Related Macular Degeneration

Adverum Biotechnologies, Inc. Presents Best-Corrected Visual Acuity and Central Subfield Thickness Analyses After A Single IVT Injection of ADVM-022 (Ixo-vec) in the OPTIC Study in Wet AMD

Adverum Biotechnologies Announces Upcoming Data Presentation at ASRS 2022

Adverum Biotechnologies, Inc. Completes IND Amendment and Prepares to Initiate Phase 2 LUNA Trial of ADVM-022 in Wet AMD

Adverum Biotechnologies, Inc.(NasdaqGM:ADVM) dropped from Russell 2000 Dynamic Index

Adverum Biotechnologies, Inc. Presents Three-Year Aflibercept Protein Expression and Improvement in Anatomic Outcomes After A Single IVT Injection of ADVM-022 in the Optic Study in Wet AMD

Adverum Biotechnologies, Inc. Announces Executive Changes

Adverum Biotechnologies Announces New Data At the Macula Society's 2022 Annual Meeting

Adverum Biotechnologies Presents Research Pipeline Data Supporting Utility of Its Proprietary Platform and AAV.7m8 Capsid in Ocular Gene Therapy

Adverum Biotechnologies, Inc. Presents Data At American Society of Gene and Cell Therapy Further Supporting Phase 2 Development Plans for ADVM-022

Adverum Biotechnologies, Inc. Presents Additional Efficacy and Safety Data from the Optic Trial of ADVM-022 in Wet AMD At the ARVO 2022 Annual Meeting

High number of new directors

Adverum Biotechnologies, Inc. Appoints Richard Beckman M.D. as Chief Medical Officer

Adverum Biotechnologies, Inc. Grants Orphan Drug Designation by FDA for Gene Therapy Candidate in Preclinical Development for the Treatment of Blue Cone Monochromacy

Adverum Biotechnologies Provides ADVM-022 Development Update and Anticipated Corporate Milestones for 2022

Independent Director recently sold US$109k worth of stock

Chief Business Officer & Acting CFO Christopher DeRespino has left the company

Adverum Biotechnologies, Inc. Provides Update on ADVM-022 and the INFINITY Trial in Patients with Diabetic Macular Edema

Adverum Biotechnologies, Inc.(NasdaqGM:ADVM) dropped from Russell 3000E Growth Index

Independent Chairman recently bought US$99k worth of stock

Lexeo Therapeutics, LLC Announces License Agreement with Adverum Biotechnologies, Inc

Adverum Biotechnologies, Inc. Appoints Reed V. Tuckson as an Independent Member to Board of Directors

Adverum Biotechnologies, Inc. Appoints Christopher J. Derespino as Chief Business Officer

Adverum Biotechnologies, Inc. Appoints Leone Patterson as Principal Financial Officer and Principal Accounting Officer

Independent Chairman recently bought US$115k worth of stock

Adverum Biotechnologies Completes Patient Enrollment for INFINITY Phase 2 Trial of ADVM-022 in DME

Adverum Biotechnologies, Inc Appoints Dawn Svoronos as Independent Member of Board of Directors

Shareholder Returns

Price Volatility

About the Company

Adverum Biotechnologies, Inc. Fundamentals Summary

150.8x

-1.6x

Earnings & Revenue